These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32509716)

  • 1. Economics of Public Antibiotics Development.
    Okhravi C
    Front Public Health; 2020; 8():161. PubMed ID: 32509716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
    Brogan DM; Mossialos E
    Global Health; 2013 Nov; 9():58. PubMed ID: 24199835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulating Market Entry Rewards for Antibiotics Development.
    Okhravi C; Callegari S; McKeever S; Kronlid C; Baraldi E; Lindahl O; Ciabuschi F
    J Law Med Ethics; 2018 Jun; 46(1_suppl):32-42. PubMed ID: 30146961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Inter)nationalising the antibiotic research and development pipeline.
    Singer AC; Kirchhelle C; Roberts AP
    Lancet Infect Dis; 2020 Feb; 20(2):e54-e62. PubMed ID: 31753765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
    Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
    Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics.
    Savic M; Årdal C
    J Law Med Ethics; 2018 Jun; 46(1_suppl):9-24. PubMed ID: 30146963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New business models for antibiotic innovation.
    So AD; Shah TA
    Ups J Med Sci; 2014 May; 119(2):176-80. PubMed ID: 24646116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Market power in the United States red meatpacking industry.
    Koontz SR
    Vet Clin North Am Food Anim Pract; 2003 Jul; 19(2):519-44. PubMed ID: 12951745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization.
    Outterson K; Rex JH
    Transl Res; 2020 Jun; 220():182-190. PubMed ID: 32165059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All.
    Bhatti T; Lum K; Holland S; Sassman S; Findlay D; Outterson K
    J Law Med Ethics; 2018 Jun; 46(1_suppl):59-65. PubMed ID: 30146959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines as alternatives to antibiotics for food producing animals. Part 1: challenges and needs.
    Hoelzer K; Bielke L; Blake DP; Cox E; Cutting SM; Devriendt B; Erlacher-Vindel E; Goossens E; Karaca K; Lemiere S; Metzner M; Raicek M; Collell Suriñach M; Wong NM; Gay C; Van Immerseel F
    Vet Res; 2018 Jul; 49(1):64. PubMed ID: 30060757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Institutional obstacles to expansion of world food production.
    Crosson PR
    Science; 1975 May; 188(4188):519-24. PubMed ID: 17740002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
    De Vecchi AF; Dratwa M; Wiedemann ME
    Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. There is no market for new antibiotics: this allows an open approach to research and development.
    Klug DM; Idiris FIM; Blaskovich MAT; von Delft F; Dowson CG; Kirchhelle C; Roberts AP; Singer AC; Todd MH
    Wellcome Open Res; 2021; 6():146. PubMed ID: 34250265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calculating indirect costs from international PEPFAR implementing partners.
    Honermann B; Sharp A; Sherwood J; Kshetry P; Jones A; O'Hagan R; Lazar L; Chandra C; Hoffmann T; Millett G
    PLoS One; 2018; 13(10):e0206425. PubMed ID: 30372464
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.